DKB 19001
Alternative Names: DKB-19001Latest Information Update: 21 Dec 2021
At a glance
- Originator DongKoo Bio&Pharma
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Hyperlipidaemia; Hypertension
Most Recent Events
- 15 Dec 2021 Phase-III clinical trials in Hyperlipidaemia in South Korea (unspecified route) as of December 2021 (DongKoo Bio&Pharma pipeline, December 2021)
- 15 Dec 2021 Phase-III clinical trials in Hypertension in South Korea (unspecified route) as of December 2021 (DongKoo Bio&Pharma pipeline, December 2021)